VectivBio AG (VECT) falls 2.00% for January 14

Equities Staff  |

Today, VectivBio Holding AG Inc’s (NASDAQ: VECT) stock fell $0.1, accounting for a 2.00% decrease. VectivBio AG opened at $5.05 before trading between $5.04 and $4.81 throughout Friday’s session. The activity saw VectivBio AG’s market cap fall to $166,671,506 on 8,648 shares -below their 30-day average of 46,966.

About VectivBio Holding AG

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).

Visit VectivBio Holding AG's profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on VectivBio Holding AG and to follow the company's latest updates, you can visit the company's profile page here: VectivBio Holding AG's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Commodities Post Strongest Gains in Over a Decade
Charlie Munger Doubles Down on Alibaba While the Fed Signals Tightening
Commodities — Assessing 2021 and Forecasting 2022



Market Movers

Sponsored Financial Content